Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014:2014:787143.
doi: 10.1155/2014/787143. Epub 2014 Jul 22.

BRCA-associated ovarian cancer: from molecular genetics to risk management

Giulia Girolimetti  1 , Anna Myriam Perrone  2 , Donatella Santini  3 , Elena Barbieri  4 , Flora Guerra  5 , Simona Ferrari  6 , Claudio Zamagni  4 , Pierandrea De Iaco  2 , Giuseppe Gasparre  1 , Daniela Turchetti  7
Affiliations
Review

BRCA-associated ovarian cancer: from molecular genetics to risk management

Giulia Girolimetti et al. Biomed Res Int. 2014.

Abstract

Ovarian cancer (OC) mostly arises sporadically, but a fraction of cases are associated with mutations in BRCA1 and BRCA2 genes. The presence of a BRCA mutation in OC patients has been suggested as a prognostic and predictive factor. In addition, the identification of asymptomatic carriers of such mutations offers an unprecedented opportunity for OC prevention. This review is aimed at exploring the current knowledge on epidemiological and molecular aspects of BRCA-associated OC predisposition, on pathology and clinical behavior of OC occurring in BRCA mutation carriers, and on the available options for managing asymptomatic carriers.

PubMed Disclaimer

References

    1. Staples J, Goodman A. PARP inhibitors in ovarian cancer. In: Díaz-Padilla I, editor. Ovarian Cancer—A Clinical and Translational Update. chapter 14. InTech; 2013.
    1. Yoshida K, Miki Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Science. 2004;95(11):866–871. - PMC - PubMed
    1. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. Journal of Clinical Oncology. 2008;26(22):3785–3790. - PubMed
    1. Banerjee S, Kaye S. PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond. Current Oncology Reports. 2011;13(6):442–449. - PubMed
    1. Scully R, Livingston DM. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature. 2000;408(6811):429–432. - PMC - PubMed

Publication types

LinkOut - more resources